FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2725876265> ?p ?o ?g. }

• W2725876265 endingPage "148" @default.
• W2725876265 startingPage "141" @default.
• W2725876265 abstract "Background: HIV-1-infected, virologically suppressed adults wanting to simplify or change their non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens may benefit from switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (E/C/F/TDF).Objective: We examined differences in the proportion of participants with HIV-1 RNA < 50 copies/mL (Snapshot analysis), change in CD4 cell count, safety, and patient-reported outcomes in participants switching to E/C/F/TDF from an NNRTI + FTC/TDF (TVD) regimen.Methods: STRATEGY-NNRTI was a 96-week, phase 3b, randomized, open-label, study examining the efficacy, safety, and tolerability of switching to E/C/F/TDF in virologically suppressed individuals (HIV-1 RNA < 50 copies/mL) on an NNRTI + TVD regimen. Participants were randomized to switch or remain on their NNRTI-based regimen (no-switch).Results: At Week 96, 87% (251/290) of switch and 80% (115/143) of no-switch participants maintained HIV-1 RNA < 50 copies/mL (difference 6.1%; 95% CI −1.3 to 14.2%; p = 0.12) according to the FDA-defined snapshot algorithm. Both groups had similar proportions of subjects with virologic failure (2.8% switch, 1.4% no-switch). Discontinuations resulting from adverse events were infrequent (3% [9/291] switch, 2% [3/143] no-switch). Three switch participants (1%) discontinued due to renal adverse events (2 of the 3 before Week 48). Switch participants reported significant improvements in neuropsychiatric symptoms by as early as Week 4, and which were maintained through Week 96.Conclusions: E/C/F/TDF is safe and effective and reduces NNRTI-associated neuropsychiatric symptoms for virologically suppressed HIV-positive adults switching from an NNRTI plus FTC/TDF-based regimen." @default.
• W2725876265 created "2017-07-14" @default.
• W2725876265 creator A5002877091 @default.
• W2725876265 creator A5024419279 @default.
• W2725876265 creator A5031995978 @default.
• W2725876265 creator A5032359240 @default.
• W2725876265 creator A5033625804 @default.
• W2725876265 creator A5037679984 @default.
• W2725876265 creator A5039463522 @default.
• W2725876265 creator A5046250018 @default.
• W2725876265 creator A5048050447 @default.
• W2725876265 creator A5058608689 @default.
• W2725876265 creator A5070917710 @default.
• W2725876265 creator A5073338719 @default.
• W2725876265 creator A5080996117 @default.
• W2725876265 date "2017-07-04" @default.
• W2725876265 modified "2023-10-16" @default.
• W2725876265 title "Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI" @default.
• W2725876265 cites W1511746833 @default.
• W2725876265 cites W1550111394 @default.
• W2725876265 cites W1981066923 @default.
• W2725876265 cites W2017404902 @default.
• W2725876265 cites W2030599394 @default.
• W2725876265 cites W2056358518 @default.
• W2725876265 cites W2061817517 @default.
• W2725876265 cites W2072527802 @default.
• W2725876265 cites W2083359555 @default.
• W2725876265 cites W2112016022 @default.
• W2725876265 cites W2115179084 @default.
• W2725876265 cites W2136559058 @default.
• W2725876265 cites W2145467751 @default.
• W2725876265 cites W2151050670 @default.
• W2725876265 cites W2154725148 @default.
• W2725876265 cites W2322864883 @default.
• W2725876265 cites W2403529429 @default.
• W2725876265 doi "https://doi.org/10.1080/15284336.2017.1338844" @default.
• W2725876265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28689453" @default.
• W2725876265 hasPublicationYear "2017" @default.
• W2725876265 type Work @default.
• W2725876265 sameAs 2725876265 @default.
• W2725876265 citedByCount "16" @default.
• W2725876265 countsByYear W27258762652018 @default.
• W2725876265 countsByYear W27258762652019 @default.
• W2725876265 countsByYear W27258762652020 @default.
• W2725876265 countsByYear W27258762652021 @default.
• W2725876265 countsByYear W27258762652023 @default.
• W2725876265 crossrefType "journal-article" @default.
• W2725876265 hasAuthorship W2725876265A5002877091 @default.
• W2725876265 hasAuthorship W2725876265A5024419279 @default.
• W2725876265 hasAuthorship W2725876265A5031995978 @default.
• W2725876265 hasAuthorship W2725876265A5032359240 @default.
• W2725876265 hasAuthorship W2725876265A5033625804 @default.
• W2725876265 hasAuthorship W2725876265A5037679984 @default.
• W2725876265 hasAuthorship W2725876265A5039463522 @default.
• W2725876265 hasAuthorship W2725876265A5046250018 @default.
• W2725876265 hasAuthorship W2725876265A5048050447 @default.
• W2725876265 hasAuthorship W2725876265A5058608689 @default.
• W2725876265 hasAuthorship W2725876265A5070917710 @default.
• W2725876265 hasAuthorship W2725876265A5073338719 @default.
• W2725876265 hasAuthorship W2725876265A5080996117 @default.
• W2725876265 hasConcept C126322002 @default.
• W2725876265 hasConcept C142462285 @default.
• W2725876265 hasConcept C159047783 @default.
• W2725876265 hasConcept C197934379 @default.
• W2725876265 hasConcept C2777068322 @default.
• W2725876265 hasConcept C2777351918 @default.
• W2725876265 hasConcept C2778375690 @default.
• W2725876265 hasConcept C2778723075 @default.
• W2725876265 hasConcept C2779778239 @default.
• W2725876265 hasConcept C2780524789 @default.
• W2725876265 hasConcept C2781413609 @default.
• W2725876265 hasConcept C2993143319 @default.
• W2725876265 hasConcept C3013748606 @default.
• W2725876265 hasConcept C71924100 @default.
• W2725876265 hasConcept C98274493 @default.
• W2725876265 hasConceptScore W2725876265C126322002 @default.
• W2725876265 hasConceptScore W2725876265C142462285 @default.
• W2725876265 hasConceptScore W2725876265C159047783 @default.
• W2725876265 hasConceptScore W2725876265C197934379 @default.
• W2725876265 hasConceptScore W2725876265C2777068322 @default.
• W2725876265 hasConceptScore W2725876265C2777351918 @default.
• W2725876265 hasConceptScore W2725876265C2778375690 @default.
• W2725876265 hasConceptScore W2725876265C2778723075 @default.
• W2725876265 hasConceptScore W2725876265C2779778239 @default.
• W2725876265 hasConceptScore W2725876265C2780524789 @default.
• W2725876265 hasConceptScore W2725876265C2781413609 @default.
• W2725876265 hasConceptScore W2725876265C2993143319 @default.
• W2725876265 hasConceptScore W2725876265C3013748606 @default.
• W2725876265 hasConceptScore W2725876265C71924100 @default.
• W2725876265 hasConceptScore W2725876265C98274493 @default.
• W2725876265 hasFunder F4320308573 @default.
• W2725876265 hasIssue "4" @default.
• W2725876265 hasLocation W27258762651 @default.
• W2725876265 hasOpenAccess W2725876265 @default.
• W2725876265 hasPrimaryLocation W27258762651 @default.
• W2725876265 hasRelatedWork W1992655257 @default.
• W2725876265 hasRelatedWork W2027284363 @default.
• W2725876265 hasRelatedWork W2136559058 @default.

• next